Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) will report its first quarter 2023 financial results on May 4, 2023, at 8:30 a.m. Eastern Time. The company will also provide a corporate update during a webcast, which will be available on its website. Liquidia is focused on developing treatments for pulmonary hypertension and has developed YUTREPIA™, an investigational inhalation powder for pulmonary arterial hypertension (PAH), which received tentative FDA approval in November 2021. For further information, a rebroadcast of the webcast will be available for 30 days following the live event.
Positive
- Upcoming first quarter 2023 financial results may show progress in product development.
- Tentative FDA approval of YUTREPIA™ could enhance revenue potential in the pulmonary hypertension market.
Negative
- None.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was -1.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.
The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) which received tentative approval from the U.S. Food and Drug Administration (FDA) in November 2021. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information
Media & Investors:
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.